Menu Search
Equities

Elekta AB (publ)

  • Add to watchlist
  • Add to portfolio
EKTAb:DEU

Elekta AB (publ)

Actions
  • Price (EUR)4.25
  • Today's Change0.05 / 1.19%
  • Shares traded0.00
  • 1 Year change-28.15%
  • Beta1.1043
Data delayed at least 15 minutes, as of Jul 08 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Elekta AB (publ) is a Sweden-based medical technology company which aims to improve, prolong and save lives through clinical solutions for treating cancer and brain disorders. The Company offers and develops systems for radiation therapy and radio-surgery, as well as software systems that enhance workflow efficiency throughout the entire spectrum of cancer care. Elekta AB (publ) develops clinical treatment solutions for radiation therapy and radiosurgery, as well as work flow-enhancing software systems, across the spectrum of cancer care. The Company provides clinical solutions for image guided radiation therapy and stereotactic radiosurgery, giving oncologists and neurosurgeons an unmatched capability to treat tumors and functional targets with ultra-high precision while sparing healthy tissue.

  • Revenue in SEK (TTM)18.02bn
  • Net income in SEK237.00m
  • Incorporated1972
  • Employees4.54k
  • Location
    Elekta AB (publ)Kungstensgatan 18STOCKHOLM 113 57SwedenSWE
  • Phone+46 858725400
  • Fax+46 858725500
  • Websitehttps://www.elekta.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.